20-236 - A Safety and Efficacy Study of Oral Venetoclax Tablets and Injectable Azacitidine Versus Best Supportive Care as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy to EvaluateStatus: open
Randomized, Open-label, 2-Arm, Multicenter, Phase 3 Study of Venetoclax and Azacitidine Versus Best Supportive Care as Maintenance Therapy for Patients with Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy (VIALE-M)
Treatment for Oncology - Acute Myeloid Leukemia
The trial will evaluate how well venetoclax in combination with azacitidine (AZA) works as compared to best supportive care (BSC) as maintenance therapy in patients with Acute Myeloid Leukemia (AML) in first remission after completion of the first chemotherapy treatment regimen.
Interested in Clinical Trial?
Providers Associated With This Trial
- Omar Alkharabsheh, M.D.Medical Oncologist and HematologistAssistant Professor of Interdisciplinary Clinical Oncology